<br>        Inclusion criteria:<br><br>          -  Males and females aged >=18 to =<80 years who have a diagnosis of moderate to severe<br>             chronic plaque psoriasis (with or without psoriatic arthritis) for at least 6 months<br>             before the first administration of study drug (a self-reported diagnosis confirmed by<br>             the investigator is acceptable), and which has been stable for the last 2 months with<br>             no changes in morphology or significant flares at both Screening and Baseline<br>             (Randomization):<br><br>               -  involved body surface area (BSA) >= 10% and<br><br>               -  Psoriasis Area and Severity Index (PASI) score >= 12 and<br><br>               -  static Physician's Global Assessment (sPGA) score of >= 3.<br><br>          -  Participants of reproductive potential (childbearing potential ) must be willing and<br>             able to use highly effective methods of birth control per International Council for<br>             Harmonization (ICH) M3 (R2) that result in a low failure rate of less than 1% per year<br>             when used consistently and correctly during the trial and for 6 months following<br>             completion or discontinuation from the trial medication.<br><br>          -  Signed and dated written informed consent in accordance with Good Clinical Practice<br>             (GCP) and local legislation prior to admission to the trial.<br><br>          -  Patients who are candidates for systemic therapy.<br><br>        Exclusion criteria:<br><br>          -  Active ongoing inflammatory diseases other than psoriasis that might confound trial<br>             evaluations according to investigator's judgment.<br><br>          -  Previous treatment with more than 1 biological agent, or adalimumab or adalimumab<br>             biosimilar. No prior biologic exposure within last 6 months of screening.<br><br>          -  Patients with a significant disease other than psoriasis and/or a significant<br>             uncontrolled disease (such as, but not limited to, nervous system, renal, hepatic,<br>             endocrine, hematological, autoimmune or gastrointestinal disorders).<br><br>          -  Major surgery performed within 12 weeks prior to randomization or planned within 6<br>             months after screening, e.g., total hip replacement.<br><br>          -  Any documented active or suspected malignancy or history of malignancy within 5 years<br>             prior to screening, except appropriately treated basal cell carcinoma of the skin or<br>             in situ carcinoma of uterine cervix.<br><br>          -  Patients who must or wish to continue the intake of restricted medications or any drug<br>             considered likely to interfere with the safe conduct of the trial.<br><br>          -  Currently enrolled in another investigational device or drug study, or less than 30<br>             days since ending another investigational device or drug study(s), or receiving other<br>             investigational treatment(s).<br><br>          -  Chronic alcohol or drug abuse<br><br>          -  Women who are pregnant, nursing, or who plan to become pregnant during the course of<br>             this study or within the period at least 6 months following completion or<br>             discontinuation from the trial.<br><br>          -  Forms of psoriasis (e.g., pustular, erythrodermic and guttate) other than chronic<br>             plaque psoriasis. Drug-induced psoriasis (i.e., new onset or current exacerbation from<br>             e.g., beta blockers or lithium).<br><br>          -  Primary or secondary immunodeficiency (history of, or currently active), including<br>             known history of HIV infection or a positive HIV test at screening (per the<br>             investigator discretion and where mandated by local authorities).<br><br>          -  Known chronic or relevant acute tuberculosis; no evidence of active tuberculosis.<br><br>          -  Known clinically significant coronary artery disease, significant cardiac arrhythmias,<br>             moderate to severe congestive heart failure (New York Heart Association Classes III or<br>             IV) or interstitial lung disease observed on chest X-ray.<br><br>          -  History of a severe allergic reaction, anaphylactic reaction, or hypersensitivity to a<br>             previously used biological drug or its excipients.<br><br>          -  Positive serology for hepatitis B virus (HBV) or hepatitis C virus (HCV).<br><br>          -  Receipt of a live/attenuated vaccine within 12 weeks prior to the Screening Visit;<br>             patients who are expecting to receive any live/attenuated virus or bacterial<br>             vaccinations during the trial or up to 3 months after the last dose of trial drug.<br><br>          -  Any treatment (including biologic therapies) that, in the opinion of the investigator,<br>             may place the patient at unacceptable risk during the trial.<br><br>          -  Known active infection of any kind (excluding fungal infections of nail beds), any<br>             major episode of infection requiring hospitalization or treatment with intravenous<br>             (i.v.) anti infectives within 4 weeks of the Screening Visit<br><br>          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 times upper<br>             limit of normal (ULN) at Screening.<br><br>          -  Hemoglobin < 8.0 g/dL at Screening.<br><br>          -  Platelets < 100,000/µL at Screening.<br><br>          -  Leukocyte count < 4000/µL at Screening.<br><br>          -  Creatinine clearance < 60 mL/min/1.73 m2 at Screening.<br><br>          -  Patients with a history of any clinically significant adverse reaction to murine or<br>             chimeric proteins, or natural rubber and latex, including serious allergic reactions.<br>